E. Ndashimye

发表

First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda

E. Arts, A. Poon, Richard Gibson, 2019, AIDS Research and Therapy.

Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure

E. Arts, Richard Gibson, M. Quiñones-Mateu, 2016, Antimicrobial Agents and Chemotherapy.

Detection of novel HIV-1 drug resistance mutations by support vector analysis of deep sequence data and experimental validation

D. Lizotte, E. Arts, A. Poon, 2019, bioRxiv.

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.

E. Arts, A. Poon, Richard Gibson, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030

E. Arts, E. Ndashimye, 2019, Infectious Diseases of Poverty.

Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection

C. Morrison, Pai-Lien Chen, C. Kwok, 2018, PLoS pathogens.

Once- versus twice-daily abacavir and lamivudine in African children: the randomised controlled ARROW Trial

M. Munjoma, W. Snowden, D. Gibb, 2016 .

Once vs twice-daily abacavir and lamivudine in African children

A. Walker, M. Munjoma, W. Snowden, 2016, AIDS.

Specialized DNA Structures Act as Genomic Beacons for Integration by Evolutionarily Diverse Retroviruses

E. Arts, Richard Gibson, Macon D. Coleman, 2020, bioRxiv.

Addressing an HIV cure in LMIC

E. Arts, Jamie F S Mann, A. Redd, 2021, Retrovirology.

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial

N. Klein, P. Musoke, D. Gibb, 2017, PLoS medicine.

High Time to Start Human Immunodeficiency Virus Type 1-Infected Patients on Integrase Inhibitors in Sub-Saharan Africa.

E. Ndashimye, 2017, The Journal of infectious diseases.

Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.

E. Arts, E. Ndashimye, 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

E. Arts, A. Poon, Michael Crawford, 2017, Infectious Diseases of Poverty.

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa

P. Easterbrook, K. Wools-Kaloustian, C. Kityo, 2017, Journal of acquired immune deficiency syndromes.

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period

E. Arts, C. Kityo, B. Rodriguez, 2013, AIDS.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.

E. Arts, M. Quiñones-Mateu, C. Kityo, 2021, The Journal of antimicrobial chemotherapy.

Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

E. Arts, A. Poon, Richard Gibson, 2018, AIDS research and human retroviruses.